TY - JOUR
T1 - 2024 Recommendations for Validation of Noninvasive Arterial Pulse Wave Velocity Measurement Devices
AU - Spronck, Bart
AU - Terentes-Printzios, Dimitrios
AU - Avolio, Alberto P
AU - Boutouyrie, Pierre
AU - Guala, Andrea
AU - Jeroncic, Ana
AU - Laurent, Stéphane
AU - Barbosa, Eduardo C D
AU - Baulmann, Johannes
AU - Chen, Chen-Huan
AU - Chirinos, Julio A
AU - Daskalopoulou, Stella S
AU - Hughes, Alun D
AU - Mahmud, Azra
AU - Mayer, Christopher C
AU - Park, Jeong Bae
AU - Pierce, Gary L
AU - Schutte, Aletta E
AU - Urbina, Elaine M
AU - Wilkinson, Ian B
AU - Segers, Patrick
AU - Sharman, James E
AU - Tan, Isabella
AU - Vlachopoulos, Charalambos
AU - Weber, Thomas
AU - Bianchini, Elisabetta
AU - Bruno, Rosa Maria
AU - Association for Research into Arterial Structure, Physiology (ARTERY) Society
AU - European Society of Hypertension Working Group on Large Arteries
AU - European Cooperation in Science and Technology Action VascAgeNet
AU - North American Artery Society
AU - ARTERY LATAM
AU - Pulse of Asia
AU - Society for Arterial Stiffness—Germany-Austria-Switzerland (DeGAG)
PY - 2024/1/1
Y1 - 2024/1/1
N2 - BACKGROUND: Arterial stiffness, as measured by arterial pulse wave velocity (PWV), is an established biomarker for cardiovascular risk and target-organ damage in individuals with hypertension. With the emergence of new devices for assessing PWV, it has become evident that some of these devices yield results that display significant discrepancies compared with previous devices. This discrepancy underscores the importance of comprehensive validation procedures and the need for international recommendations. METHODS: A stepwise approach utilizing the modified Delphi technique, with the involvement of key scientific societies dedicated to arterial stiffness research worldwide, was adopted to formulate, through a multidisciplinary vision, a shared approach to the validation of noninvasive arterial PWV measurement devices. RESULTS: A set of recommendations has been developed, which aim to provide guidance to clinicians, researchers, and device manufacturers regarding the validation of new PWV measurement devices. The intention behind these recommendations is to ensure that the validation process can be conducted in a rigorous and consistent manner and to promote standardization and harmonization among PWV devices, thereby facilitating their widespread adoption in clinical practice. CONCLUSIONS: It is hoped that these recommendations will encourage both users and developers of PWV measurement devices to critically evaluate and validate their technologies, ultimately leading to improved consistency and comparability of results. This, in turn, will enhance the clinical utility of PWV as a valuable tool for assessing arterial stiffness and informing cardiovascular risk stratification and management in individuals with hypertension.
AB - BACKGROUND: Arterial stiffness, as measured by arterial pulse wave velocity (PWV), is an established biomarker for cardiovascular risk and target-organ damage in individuals with hypertension. With the emergence of new devices for assessing PWV, it has become evident that some of these devices yield results that display significant discrepancies compared with previous devices. This discrepancy underscores the importance of comprehensive validation procedures and the need for international recommendations. METHODS: A stepwise approach utilizing the modified Delphi technique, with the involvement of key scientific societies dedicated to arterial stiffness research worldwide, was adopted to formulate, through a multidisciplinary vision, a shared approach to the validation of noninvasive arterial PWV measurement devices. RESULTS: A set of recommendations has been developed, which aim to provide guidance to clinicians, researchers, and device manufacturers regarding the validation of new PWV measurement devices. The intention behind these recommendations is to ensure that the validation process can be conducted in a rigorous and consistent manner and to promote standardization and harmonization among PWV devices, thereby facilitating their widespread adoption in clinical practice. CONCLUSIONS: It is hoped that these recommendations will encourage both users and developers of PWV measurement devices to critically evaluate and validate their technologies, ultimately leading to improved consistency and comparability of results. This, in turn, will enhance the clinical utility of PWV as a valuable tool for assessing arterial stiffness and informing cardiovascular risk stratification and management in individuals with hypertension.
KW - aorta
KW - cardiovascular diseases
KW - guideline
KW - pulse wave analysis
KW - vascular stiffness
U2 - 10.1161/HYPERTENSIONAHA.123.21618
DO - 10.1161/HYPERTENSIONAHA.123.21618
M3 - Article
SN - 0194-911X
VL - 81
SP - 183
EP - 192
JO - Hypertension
JF - Hypertension
IS - 1
ER -